These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28423213)

  • 1. Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.
    Urnauer S; Klutz K; Grünwald GK; Morys S; Schwenk N; Zach C; Gildehaus FJ; Rödl W; Ogris M; Wagner E; Spitzweg C
    J Gene Med; 2017 May; 19(5):. PubMed ID: 28423213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.
    Klutz K; Willhauck MJ; Dohmen C; Wunderlich N; Knoop K; Zach C; Senekowitsch-Schmidtke R; Gildehaus FJ; Ziegler S; Fürst S; Göke B; Wagner E; Ogris M; Spitzweg C
    Hum Gene Ther; 2011 Dec; 22(12):1563-74. PubMed ID: 21851208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.
    Klutz K; Schaffert D; Willhauck MJ; Grünwald GK; Haase R; Wunderlich N; Zach C; Gildehaus FJ; Senekowitsch-Schmidtke R; Göke B; Wagner E; Ogris M; Spitzweg C
    Mol Ther; 2011 Apr; 19(4):676-85. PubMed ID: 21245850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.
    Urnauer S; Morys S; Krhac Levacic A; Müller AM; Schug C; Schmohl KA; Schwenk N; Zach C; Carlsen J; Bartenstein P; Wagner E; Spitzweg C
    Mol Ther; 2016 Aug; 24(8):1395-404. PubMed ID: 27157666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
    Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
    Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
    Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
    Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
    Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
    J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (
    Schug C; Kitzberger C; Sievert W; Spellerberg R; Tutter M; Schmohl KA; Eberlein B; Biedermann T; Steiger K; Zach C; Schwaiger M; Multhoff G; Wagner E; Nelson PJ; Spitzweg C
    Clin Cancer Res; 2019 Oct; 25(19):5997-6008. PubMed ID: 31196853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene.
    Knoop K; Schwenk N; Schmohl K; Müller A; Zach C; Cyran C; Carlsen J; Böning G; Bartenstein P; Göke B; Wagner E; Nelson PJ; Spitzweg C
    J Nucl Med; 2015 Apr; 56(4):600-6. PubMed ID: 25745085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-targeted NIS polyplexes-a theranostic strategy toward tumors with heterogeneous receptor expression.
    Urnauer S; Schmohl KA; Tutter M; Schug C; Schwenk N; Morys S; Ziegler S; Bartenstein P; Clevert DA; Wagner E; Spitzweg C
    Gene Ther; 2019 Apr; 26(3-4):93-108. PubMed ID: 30683895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer.
    Schug C; Urnauer S; Jaeckel C; Schmohl KA; Tutter M; Steiger K; Schwenk N; Schwaiger M; Wagner E; Nelson PJ; Spitzweg C
    Endocr Relat Cancer; 2019 Jan; 26(1):89-101. PubMed ID: 30121623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma.
    Knoop K; Schwenk N; Dolp P; Willhauck MJ; Zischek C; Zach C; Hacker M; Göke B; Wagner E; Nelson PJ; Spitzweg C
    Hum Gene Ther; 2013 Mar; 24(3):306-16. PubMed ID: 23402366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases.
    Urnauer S; Müller AM; Schug C; Schmohl KA; Tutter M; Schwenk N; Rödl W; Morys S; Ingrisch M; Bertram J; Bartenstein P; Clevert DA; Wagner E; Spitzweg C
    Oncotarget; 2017 Nov; 8(54):92195-92208. PubMed ID: 29190908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.
    Klutz K; Willhauck MJ; Wunderlich N; Zach C; Anton M; Senekowitsch-Schmidtke R; Göke B; Spitzweg C
    Hum Gene Ther; 2011 Nov; 22(11):1403-12. PubMed ID: 21488714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.
    Müller AM; Schmohl KA; Knoop K; Schug C; Urnauer S; Hagenhoff A; Clevert DA; Ingrisch M; Niess H; Carlsen J; Zach C; Wagner E; Bartenstein P; Nelson PJ; Spitzweg C
    Oncotarget; 2016 Aug; 7(34):54795-54810. PubMed ID: 27458162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (
    Tutter M; Schug C; Schmohl KA; Urnauer S; Schwenk N; Petrini M; Lokerse WJM; Zach C; Ziegler S; Bartenstein P; Weber WA; Wagner E; Lindner LH; Nelson PJ; Spitzweg C
    Theranostics; 2020; 10(10):4490-4506. PubMed ID: 32292510
    [No Abstract]   [Full Text] [Related]  

  • 18. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.
    Knoop K; Kolokythas M; Klutz K; Willhauck MJ; Wunderlich N; Draganovici D; Zach C; Gildehaus FJ; Böning G; Göke B; Wagner E; Nelson PJ; Spitzweg C
    Mol Ther; 2011 Sep; 19(9):1704-13. PubMed ID: 21587211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
    Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
    J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
    Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
    Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.